How much does Zolbetuximab-Vyloy cost in Japan?

Zolbetuximab, trade name Vyloy, is a targeted therapy drug used to treat Claudin 18.2-positive gastric cancer and gastroesophageal junction adenocarcinoma (GEJ adenocarcinoma). The drug is currently approved in several countries and sold globally. In Japan, Vyloy, as a new anti-cancer drug, has also entered the market to a certain extent. However, due to its particularity as an innovative drug, the price is relatively high, and whether it has been included in medical insurance is still changing.

Based on current market conditions, Vyloy is usually more expensive in Japan. Taking the common 100mg specification as an example, the price of Vyloy is about RMB 7,000 or more. This price will be affected by multiple factors such as exchange rate fluctuations, tax policies, and drug pricing strategies, so the actual price may fluctuate. For patients who require long-term use, the cost of treatment is a significant burden.

It should be noted that althoughVyloy is a highly effective targeted therapy drug with significant efficacy, it is still a high-priced drug. The price of Vyloy currently on the Japanese market is relatively high, which poses a major financial challenge to patients. Therefore, many patients may need to consider ways to mitigate the cost of treatment through insurance, drug reimbursement, or other avenues.

In addition, there are currently no generic drugs of zotuximab on the market, which means that patients can only choose to purchase the original drug. As the drug market develops, more treatment options may become available in the future, and prices may change as a result. However, the development and launch of generic drugs usually takes a certain amount of time, so patients still have to face the higher purchase cost of original drugs.

Reference: https://medlineplus.gov/druginfo/meds/a624072.html